Clinical Trial Update: Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of Boehringer Ingelheim's BIRB 796 BS in moderate to severe Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• BIRB 796 BS (BIRB 796)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Crohn Disease | Phase 2 | Status: TERMINATED